Compare SOLS & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOLS | ASND |
|---|---|---|
| Founded | 2025 | 2006 |
| Country | United States | Denmark |
| Employees | 4400 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 13.6B |
| IPO Year | N/A | 2014 |
| Metric | SOLS | ASND |
|---|---|---|
| Price | $71.93 | $229.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $72.75 | ★ $278.80 |
| AVG Volume (30 Days) | ★ 3.2M | 718.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.46 | $98.02 |
| Revenue Next Year | $5.00 | $43.13 |
| P/E Ratio | $54.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.43 | $124.06 |
| 52 Week High | $84.44 | $248.60 |
| Indicator | SOLS | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 49.46 |
| Support Level | $47.09 | $190.49 |
| Resistance Level | $83.07 | $245.30 |
| Average True Range (ATR) | 3.23 | 9.40 |
| MACD | -1.22 | -0.89 |
| Stochastic Oscillator | 21.40 | 35.92 |
Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.